Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Biopharm Drug Dispos ; 28(6): 283-9, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17570125

RESUMEN

It has been shown that the expression of the morphine (MOR) withdrawal syndrome precipitated by naloxone (NAL) is more intense in male mice than in females, but the reasons for this phenomenon remain uncertain. The purpose of the present study was to evaluate whether this sexual dimorphism might be due to differences in MOR and/or NAL plasma levels after a chronic treatment with MOR. Prepubertal Swiss male and female mice were rendered dependent by intraperitoneal (i.p.) injection of MOR (2 mg/kg), twice daily for 9 days. On day 10 dependent mice received NAL (6 mg/kg, i.p.) 60 min after MOR injection. Blood samples were taken at different times in order to determine MOR and NAL plasma levels by gas chromatography-mass spectrometry (GC-MS) and high-performance liquid chromatography (HPLC), respectively. Pharmacokinetic analysis showed no differences between male and female mice either for MOR or for NAL. In conclusion, although males and females respond differentially to NAL-precipitated withdrawal, this dimorphic behavior would not be influenced by a pharmacokinetic factor.


Asunto(s)
Morfina/farmacocinética , Naloxona/farmacocinética , Síndrome de Abstinencia a Sustancias/metabolismo , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/farmacocinética , Animales , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Femenino , Cromatografía de Gases y Espectrometría de Masas , Semivida , Inyecciones Intraperitoneales , Masculino , Ratones , Morfina/administración & dosificación , Dependencia de Morfina/sangre , Dependencia de Morfina/complicaciones , Naloxona/administración & dosificación , Naloxona/sangre , Antagonistas de Narcóticos/administración & dosificación , Antagonistas de Narcóticos/farmacocinética , Factores Sexuales , Maduración Sexual , Síndrome de Abstinencia a Sustancias/etiología , Factores de Tiempo
2.
J Anal Toxicol ; 30(4): 258-61, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16803664

RESUMEN

This report describes a specific and precise high-performance liquid chromatography (HPLC) method for the quantification of trans,trans-muconic acid in human urine. The procedure involved a highly efficient Bond-Elut SAX extraction with 20% acetic acid elution. The HPLC analysis used a sodium acetate/methanol mobile phase with a C18 reverse phase column and UV detection at 265 nm. The recovery, precision, linearity, and limits of detection and quantification of the method were determined. Mean absolute recoveries were between 97% and 115%. The calibration curve showed a correlation coefficient of 0.9955 and the limit of detection was determined to be 10.8 microg/L. The method is suitable for evaluation of occupational and environmental benzene exposure in humans. The study of urinary trans,trans-muconic acid of two populations of children to evaluate environmental benzene exposure is presented.


Asunto(s)
Contaminantes Atmosféricos/metabolismo , Benceno/metabolismo , Ácido Sórbico/análogos & derivados , Orina/química , Adulto , Argentina , Biomarcadores , Niño , Cromatografía Líquida de Alta Presión/métodos , Ciudades , Monitoreo del Ambiente/métodos , Humanos , Reproducibilidad de los Resultados , Ácido Sórbico/análisis
3.
Pain ; 105(1-2): 265-73, 2003 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-14499444

RESUMEN

To determine the potential clinical utility of peripheral opioid action using a clinical model of cancer treatment-induced inflammation and pain that allowed for topical application of morphine in the damaged tissue (oral mucosa). This pilot study followed a two blocks design. Ten patients with painful oral mucositis were enrolled in the first block (dose-response relationship finding) and randomized in two groups to receive oral rinses with 15 ml of either 1 per thousand or 2 per thousand morphine solution. Twenty-two patients were enrolled into the second block (efficacy and safety determination). Additionally, serum concentrations of morphine were measured in five representative patients. In the first block (n=10) a dose-response relationship for topical morphine was found. Rinses with 2 per thousand -morphine solution showed better pain relief (median 80%, range 70-80%) than those with 1 per thousand (median 60%, range 55-70%; P=0.0238). Therefore, subsequent patients enrolled for the second block (n=22) received oral rinses with 2 per thousand -morphine solution. In these patients the time to good (>or=50%) or to complete (100%) pain relief was 28 (+/-12)min after the first mouthwash, and the duration of relief was on average 216 (+/-25)min. Twenty patients (90%) received the successive mouthwashes every 3 h and 10% of them every 2 h. The duration of severe pain at the moment of swallowing was 5.17 (+/-1.47) days. Only six patients needed supplementary analgesia, and the time elapsed before the first supplemental analgesic was 1.18 (+/-0.8) days. The duration of severe functional impairment was 1.52 (+/-1.31) days, thus allowing us to feed the patient by mouth with liquid-food supplementation. During our experiment no systemically active detectable concentrations of morphine were found (GC-MS analysis). The most important side effect attributable to morphine mouthwashes was burning/itching sensation (very mild to mild intensity). Patients with painful chemoradiotherapy-induced stomatitis could be alleviated using topical morphine mouthwashes.


Asunto(s)
Analgésicos Opioides/uso terapéutico , Morfina/uso terapéutico , Dolor/tratamiento farmacológico , Dolor/etiología , Estomatitis/complicaciones , Administración Oral , Administración Tópica , Anciano , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/efectos adversos , Analgésicos Opioides/farmacocinética , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Persona de Mediana Edad , Morfina/administración & dosificación , Morfina/efectos adversos , Morfina/farmacocinética , Bloqueo Nervioso , Dolor/fisiopatología , Dimensión del Dolor , Proyectos Piloto , Soluciones , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...